X4 Pharmaceuticals Book Value Per Share Growth & History (XFOR)
X4 Pharmaceuticals's book value per share was $2.05 for fiscal 2025.
View full X4 Pharmaceuticals company overviewX4 Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.05 | -$1.84 | −47.28% |
| 2024 | 2024-12-31 | $3.89 | -$5.28 | −57.59% |
| 2023 | 2023-12-31 | $9.16 | -$9.11 | −49.86% |
| 2022 | 2022-12-31 | $18.28 | -$50.49 | −73.42% |
| 2021 | 2021-12-31 | $68.77 | -$65.30 | −48.71% |
| 2020 | 2020-12-31 | $134.07 | -$106.52 | −44.27% |
| 2019 | 2019-12-31 | $240.59 | $6,823.51 | — |
| 2018 | 2018-12-31 | -$6,582.91 | -$6,021.54 | — |
| 2017 | 2017-12-31 | -$561.38 | $7,525.22 | — |
| 2016 | 2016-12-31 | -$8,086.59 | — | — |
X4 Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.62 | $1.12 | +224.21% |
| Q1 2026 | 2026-03-31 | $1.79 | -$2.18 | −54.94% |
| Q4 2025 | 2025-12-31 | $2.05 | -$1.84 | −47.28% |
| Q3 2025 | 2025-09-30 | $2.45 | -$8.17 | −76.94% |
| Q2 2025 | 2025-06-30 | $0.50 | -$16.36 | −97.04% |
| Q1 2025 | 2025-03-31 | $3.96 | $3.78 | +2039.53% |
| Q4 2024 | 2024-12-31 | $3.89 | -$5.28 | −57.59% |
| Q3 2024 | 2024-09-30 | $10.62 | -$1.70 | −13.79% |
| Q2 2024 | 2024-06-30 | $16.86 | $4.53 | +36.71% |
| Q1 2024 | 2024-03-31 | $0.19 | -$12.51 | −98.54% |
| Q4 2023 | 2023-12-31 | $9.16 | -$9.11 | −49.86% |
| Q3 2023 | 2023-09-30 | $12.32 | -$14.70 | −54.39% |
| Q2 2023 | 2023-06-30 | $12.33 | -$16.81 | −57.67% |
| Q1 2023 | 2023-03-31 | $12.70 | -$35.76 | −73.79% |
| Q4 2022 | 2022-12-31 | $18.28 | -$50.49 | −73.42% |
| Q3 2022 | 2022-09-30 | $27.02 | -$56.45 | −67.63% |
| Q2 2022 | 2022-06-30 | $29.14 | -$77.54 | −72.68% |
| Q1 2022 | 2022-03-31 | $48.46 | -$86.22 | −64.02% |
| Q4 2021 | 2021-12-31 | $68.77 | -$65.30 | −48.71% |
| Q3 2021 | 2021-09-30 | $83.47 | -$81.94 | −49.54% |
| Q2 2021 | 2021-06-30 | $106.68 | -$88.03 | −45.21% |
| Q1 2021 | 2021-03-31 | $134.68 | -$86.32 | −39.06% |
| Q4 2020 | 2020-12-31 | $134.07 | -$106.52 | −44.27% |
| Q3 2020 | 2020-09-30 | $165.41 | -$25.61 | −13.41% |
| Q2 2020 | 2020-06-30 | $194.71 | -$37.64 | −16.20% |
| Q1 2020 | 2020-03-31 | $221.00 | $89.52 | +68.09% |
| Q4 2019 | 2019-12-31 | $240.59 | $6,823.51 | — |
| Q3 2019 | 2019-09-30 | $191.02 | $1,022.72 | — |
| Q2 2019 | 2019-06-30 | $232.35 | $958.29 | — |
| Q1 2019 | 2019-03-31 | $131.48 | $784.36 | — |
| Q4 2018 | 2018-12-31 | -$6,582.91 | -$6,021.54 | — |
| Q3 2018 | 2018-09-30 | -$831.70 | — | — |
| Q2 2018 | 2018-06-30 | -$725.94 | — | — |
| Q1 2018 | 2018-03-31 | -$652.88 | — | — |
| Q4 2017 | 2017-12-31 | -$561.38 | — | — |
X4 Pharmaceuticals book value per share trends
Over the last five fiscal years, X4 Pharmaceuticals's book value per share decreased from $134.07 to $2.05, a change of -$132.02. The latest reported quarter, Q2 2026, shows $1.62.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review X4 Pharmaceuticals source filings ↗